Alterity Therapeutics Ltd. (AU:ATH) has released an update.
Alterity Therapeutics, a biotech firm focused on treatments for neurodegenerative diseases, is slated to present at an MST Financial Webinar, inviting investors and shareholders to join on 25 July 2024. During the event, participants will learn about the company’s progress and future plans, particularly regarding their lead asset, ATH434, which is in Phase 2 trials for Multiple System Atrophy. Registration is required for the webinar, which also offers a live Q&A session.
For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.
